Cost-effectiveness analysis of collaborative treatment of late-life depression in primary care (GermanIMPACT)
- 15 January 2019
- journal article
- research article
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 57, 10-18
Abstract
Background: Late-life depression is a highly prevalent disorder that causes a large economic burden. A stepped collaborative care program was set up in order to improve care for patients with late-life depression in primary care in Germany: GermanIMPACT is the adaption of the Improving Mood-Promoting Access to Collaborative Treatment (IMPACT) program that has already been established in primary care in the USA. The aim of this study was to determine the cost-effectiveness of GermanIMPACT compared with treatment as usual from a societal perspective.Methods: This study is part of a 12-month bi-centric cluster-randomized controlled trial aiming to assess the effectiveness of GermanIMPACT compared with treatment as usual among patients with late-life depression. A cost-effectiveness analysis using depression-free days (DFDs) was performed. Net-monetary benefit (NMB) regressions adjusted for baseline differences for different willingness-to-pay (WTP) thresholds were conducted and cost-effectiveness acceptability curves were constructed.Results: In total, n = 246 patients (intervention group: n = 139; control group: n = 107) with a mean age of 71 from 71 primary care practices were included in the analysis. After 12 months, adjusted mean differences in costs and DFDs between intervention group and control group were +€354 and +21.4, respectively. Only the difference in DFDs was significant (p = 0.022). According to the unadjusted incremental cost-effectiveness ratio, GermanIMPACT was dominant compared with treatment as usual. The probability of GermanIMPACT being cost-effective was 80%, 90% or 95% if societal WTP per DFD was ≥€70, ≥€110 or ≥€180, respectively.Conclusion: Evidence for cost-effectiveness of GermanIMPACT relative to treatment as usual is not clear. Only if societal WTP was ≥€180 for an additional DFD, GermanIMPACT could be considered cost-effective with certainty.Keywords
Funding Information
- German Federal Ministry of Education and Research (01GY1142)
This publication has 41 references indexed in Scilit:
- The economic cost of brain disorders in EuropeEuropean Journal of Neurology, 2011
- Problem-Solving Therapy and Supportive Therapy in Older Adults With Major Depression and Executive DysfunctionArchives of General Psychiatry, 2011
- The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic reviewGeneral Hospital Psychiatry, 2010
- Cost-effectiveness of a stepped care intervention to prevent depression and anxiety in late life: randomised trialThe British Journal of Psychiatry, 2010
- Die Bedeutung psychischer Beschwerden für die medizinische Inanspruchnahme und das Krankheitsverhalten ÄltererPsychiatrische Praxis, 2008
- Depression-Free Days as a Summary Measure of the Temporal Pattern of Response and Remission in the Treatment of Major DepressionThe Journal of Clinical Psychiatry, 2003
- Mental Disorder in Elderly Suicides: A Case-Control StudyAmerican Journal of Psychiatry, 2002
- Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost‐effectiveness analysisHealth Economics, 2002
- The PHQ-9Journal of General Internal Medicine, 2001
- An Efficient Method of Estimating Seemingly Unrelated Regressions and Tests for Aggregation BiasJournal of the American Statistical Association, 1962